MDX-33: Phase II

MEDX and partner Aventis Behring L.L.C. (King of Prussia, Penn.) said that in a dose-escalation Phase II trial in 30 patients with chronic ITP, a single dose of 5 mg/m 2 of MDX-33 transiently increase...